Search JAGX
Jaguar Health, Inc.
NasdaqCM · CIK 1585608
Last close3.66
Daily change-0.29 (-7.34%)
10 Years gain-100.00%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
JAGX · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1213
Fundamental
28.6Momentum
100.0Acceleration
100.0Confidence
62.0Annual Revenue12
Quarterly Revenue30
Annual CFO10
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth11.1 / 25
Quality12.5 / 25
Capital Efficiency0.0 / 20
Balance Sheet0.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators5.0 / 5
Signals
Gross margin expansionGross margin improved by 5.8737 percentage points.
Operating leverageOperating margin improved by 231.3908 percentage points.
Warnings
Heavy share dilution · HIGHDiluted share count increased 4419.2248%.
Low interest coverage · HIGHInterest coverage is -14.37x.
Key Metrics
Revenue Growth TTM138.56%OK
Revenue CAGR 3Y-1.26%OK
Gross Margin88.21%OK
Operating Margin-45.94%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y4,419.22%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $11.51M | $7.74M | -$45.91M | -$23.69M | n/a | 67.21% | -398.82% | n/a | n/a | 2.33M |
| 2025 FY Dec 31, 2024 | $11.69M | $9.73M | -$30.83M | -$29.38M | -$29.40M | 83.27% | -263.76% | -251.52% | n/a | 294,534 |
| 2024 FY Dec 31, 2023 | $9.76M | $7.72M | -$34.29M | -$33.24M | n/a | 79.13% | -351.31% | n/a | n/a | 15,421 |
| 2023 FY Dec 31, 2022 | n/a | $9.94M | -$34.42M | -$33.10M | -$33.18M | n/a | n/a | n/a | n/a | 1.31M |
| 2022 FY Dec 31, 2022 | $11.96M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $27.56M | sum latest 4 fiscal quarters Revenue | OK | 0001193125-26-356570, 0001193125-25-282950 |
| Revenue Growth TTM | 138.56% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-26-356570, 0001193125-25-282950 |
| Revenue CAGR 3Y | -1.26% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-144470 |
| Revenue CAGR 5Y | 4.17% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001193125-26-144470 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001193125-26-144470 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001193125-26-356570, 0001193125-25-282950 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 88.21% | Gross Profit / Revenue | OK | 0001193125-26-356570, 0001193125-25-282950 |
| Operating Margin | -45.94% | Operating Income / Revenue | OK | 0001193125-26-356570, 0001193125-25-282950 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001193125-26-356570 |
| Interest Coverage | -14.37x | Operating Income / abs(Interest Expense) | OK | derived |
| Current Ratio | 0.69x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $34.06 | Revenue / Diluted Shares | OK | 0001193125-26-356570, 0001193125-25-282950 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |